secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2025-02-14T23:59:59+00:00
Accession:  0000950170-25-020424
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus CRB-701 Phase 1 Western data: low neuropathy, HNSCC responses, dose optimization started
--------------------------------------------------------------------------------

- No DLTs; peripheral neuropathy 5% (Grade 1-2) vs 3% in China; combined 4% across 75 patients.
- Ocular AEs lower in Western study (38% vs 66%) with proactive prevention protocol at 2.7/3.6 mg/kg.
- Efficacy: 4 PR in HNSCC (n=7); 1 CR in cervical; mUC responses despite prior EV treatment.
- PK comparable to China; CRB-701 shows longer ADC half-life and lower free-MMAE vs enfortumab vedotin.
- Dose optimization randomized at 2.7 and 3.6 mg/kg Q3W in HNSCC, cervical, and mUC cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025020424/0000950170-25-020424-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017025020424/crbp-20250214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-020424

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer